Tuesday, July 21, 2009

Neural stem cells offer potential treatment for Alzheimer's disease

Source: University of California - Irvine
Date: July 21, 2009

Summary:

UC Irvine scientists have shown for the first time that neural stem cells can rescue memory in mice with advanced Alzheimer's disease, raising hopes of a potential treatment for the leading cause of elderly dementia that afflicts 5.3 million people in the U.S.
Mice genetically engineered to have Alzheimer's performed markedly better on memory tests a month after mouse neural stem cells were injected into their brains. The stem cells secreted a protein that created more neural connections, improving cognitive function.
"Essentially, the cells were producing fertilizer for the brain," said Frank LaFerla, director of UCI's Institute for Memory Impairments and Neurological Disorders, or UCI MIND, and co-author of the study, which appears online the week of July 20 in the Proceedings of the National Academy of Sciences.

Skin-like Tissue Developed from Human Embryonic Stem Cells

Source: Tufts University
Date: July 21, 2009

Summary:

Dental and tissue engineering researchers at Tufts University School of Dental Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts have harnessed the pluripotency of human embryonic stem cells (hESC) to generate complex, multilayer tissues that mimic human skin and the oral mucosa (the moist tissue that lines the inside of the mouth). The proof-of-concept study is published online in advance of print in Tissue Engineering Part A.

Monday, July 20, 2009

Induced pluripotent stem cells repair heart, study shows

Source: Mayo Clinic
Date: July 20, 2009

Summary:

In a proof-of-concept study, Mayo Clinic investigators have demonstrated that induced pluripotent stem (iPS) cells can be used to treat heart disease. iPS cells are stem cells converted from adult cells. In this study, the researchers reprogrammed ordinary fibroblasts, cells that contribute to scars such as those resulting from a heart attack, converting them into stem cells that fix heart damage caused by infarction. The findings appear in the current online issue of the journal Circulation.

This is the first application of iPS-based technology for heart disease therapy. Previously iPS cells have been used on only three other disease models: Parkinson's disease, sickle cell anemia and hemophilia A. The ultimate goal is to use iPS cells derived from patients to repair injury. Using a person's own cells in the process eliminates the risk of rejection and the need for anti-rejection drugs. One day this regenerative medicine strategy may alleviate the demand for organ transplantation limited by donor shortage, the researchers say.

Discovery of Genetic Toggle Switch Moves Science Closer to Possible Diabetes Cure

Source: Cincinnati Children's Hospital Medical Center
Date: July 20, 2009

Summary:

Scientists have identified a master regulator gene for early embryonic development of the pancreas and other organs, putting researchers closer to coaxing stem cells into pancreatic cells as a possible cure for type1 diabetes. Researchers at Cincinnati Children's Hospital Medical Center report their findings in the July 21 Developmental Cell.

Besides having important implications in diabetes research, the study offers new insights into congenital birth defects involving the pancreas and biliary system by concluding both organs share a common cellular ancestry in the early mouse embryo. This discovery reverses a long standing belief that the biliary systems origin is connected to early embryonic formation of the liver, the researchers said. The pancreas regulates digestion and blood sugar, and the biliary system is vital for digestion. If the organs do not form properly during fetal development, it can be fatal. The study reports that one gene, Sox17 (a transcription factor that controls which genes are turned on or off in a cell) is the key regulator for giving instruction to cells in early mouse embryos to become either a pancreatic cell or part of the biliary system.

Students Embed Stem Cells in Sutures to Enhance Healing

Source: Johns Hopkins University
Date: July 20, 2009

Summary:

Johns Hopkins biomedical engineering students have demonstrated a practical way to embed a patient’s own adult stem cells in the surgical thread that doctors use to repair serious orthopedic injuries such as ruptured tendons. The goal, the students said, is to enhance healing and reduce the likelihood of re-injury without changing the surgical procedure itself.

Researchers discover genetic circuit that regulates behavior of stem cells

Source: Universitat Politčcnica de Catalunya
Date: July 20, 2009

Summary:

Jordi Garcia Ojalvo -- a lecturer at the Department of Physics and Nuclear Engineering of the Universitat Politčcnica de Catalunya’s School of Industrial and Aeronautical Engineering of Terrassa (ETSEIAT, Spain) -- has discovered the genetic circuit that controls the behavior of embryonic stem cells. The discovery was made in collaboration with University of Cambridge researchers. The process by which a stem cell is transformed into another type of cell is called differentiation, and the ability to change into other cell types is known as pluripotentiality.

Up until now it was generally believed in the international scientific community that embryonic stem cells are in a state of biochemical repose, static, awaiting a signal that causes them to differentiate, that gives them the initial trait which leads them to become bone, blood or skin cells, or any other type of cell of which an organism is composed. Jordi Garcia Ojalvo, one of the coordinators of the Nonlinear Dynamics, Nonlinear Optics and Lasers research group at the UPC’s Terrassa Campus, has discovered that this view is not correct, and that in fact the state of pluripotentiality in stem cells is anything but static.

Greater efficiency in generating new cells.

In a paper published this July in the prestigious journal PLoS Biology, Jordi Garcia Ojalvo and the group headed by University of Cambridge researcher Alfonso Martínez Arias say that the pluripotentiality of embryonic stem cells is not static and that these cells are in fact constantly changing. Garcia-Ojalvo and Martínez-Arias also found that there is always a subset of stem cells that are on alert, ready to respond to the signals that trigger the process of transformation known as differentiation. This ensures that an embryo’s differentiation program is completed correctly and with the necessary speed.

Saturday, July 18, 2009

Placentas found to be rich in stem cells

Source: San Francisco Chronicle
Date: July 18, 2009

Summary:

The San Francisco Chronicle reports researchers have discovered that placentas contain stem cells that can treat blood diseases:

"Bay Area researchers have found that human placentas - typically tossed as medical waste after birth - are full of the kind of stem cells that can treat leukemia and dozens of other diseases of the blood. Placental stem cells, much like the cells retrieved from umbilical cord blood, do not have the broad potential of embryonic stem cells that can turn into nearly any kind of tissue or organ in the body. But they can replace some cells and help rebuild entire systems damaged by disease."

Wednesday, July 15, 2009

Environmental factors instruct lineage choice of blood progenitor cells

Source: Helmholtz Zentrum München
Date: July 15, 2009

Summary:

The research team led by Dr. Timm Schroeder, stem cell researcher at Helmholtz Zentrum Muenchen, Germany, has developed a new bioimaging method for observing the differentiation of hematopoietic progenitor cells (HPC) at the single-cell level. With this method the researchers were able to prove for the first time that not only cell-intrinsic mechanisms, but also external environmental factors such as growth factors can control HPC lineage choice directly. The findings, published in the current issue of the prestigious journal Science, provide an essential building block for understanding the molecular mechanisms of hematopoiesis and are an important prerequisite for optimizing therapeutic stem cell applications.

Timing is everything: Growth factor keeps brain development on track

Source: Salk Institute
Date: July 15, 2009

Summary:

Just like a conductor cueing musicians in an orchestra, Fgf10, a member of the fibroblast growth factor (Ffg) family of morphogens, lets brain stem cells know that the moment to get to work has arrived, ensuring that they hit their first developmental milestone on time, report scientists at the Salk Institute for Biological Studies in the July 16, 2009, edition of the journal Neuron. Their findings not only add new insights into brain development and a novel function for Fgfs, but also reveal a possible mechanism for the selective expansion of specific brain areas over the course of evolution, such as the greatly increased size of the frontal lobe in humans.

Monday, July 13, 2009

The dormant potential of damaged nerve cells: Damaged neurons in the spinal cord retain their ability to grow

Source: Max Planck Institute
Date: July 13, 2009

Summary:

Damaged nerve cells in a finger will regrow, but those in the spinal cord do not. Why the difference? Scientists at the Max Planck Institute for Neurobiology working with an international team of researchers can now explain two important details. Nerve cells in the spinal cord still have the ability to grow even many weeks after an injury. However, the regeneration is prevented by scar tissue created after the injury occurs. Now that they have this knowledge, scientists can search for ways to reduce the scar tissue and activate the relevant growth mechanisms. ( Current Biology, June 2009)

Thursday, July 09, 2009

Research May Hold Key to Maintaining Embryonic Stem Cells in Lab

Source: UT Southwestern Medical Center
Date: July 9, 2009

Summary:

In a new study that could transform embryonic stem cell (ES cell) research, scientists at UT Southwestern Medical Center have discovered why mouse ES cells can be easily grown in a laboratory while other mammalian ES cells are difficult, if not impossible, to maintain. If the findings in mice can be applied to other animals, scientists could have an entirely new palette of research tools to work with, said Dr. Steven McKnight, chairman of biochemistry at UT Southwestern and senior author of the study appearing in the July 9 issue of Science Express.

According to the research, the activation of a gene called TDH in mouse ES cells results in the cells entering a unique metabolic state that is similar to that of rapidly growing bacterial cells. The gene controls the production of the threonine dehydrogenase (TDH) enzyme in mouse ES cells. This enzyme breaks down an amino acid called threonine into two products. One of the two products goes on to control a cellular process called one carbon metabolism; the other provides ES cells with an essential metabolic fuel.

New Role Discovered for Molecule Important in Development of Pancreas

Source: University of Pennsylvania School of Medicine
Date: July 9, 2009

Summary:

PHILADELPHIA – For years researchers have been searching for a way to treat diabetics by reactivating their insulin-producing beta cells, to no avail. Now, they may be one step closer, according to new studies published by researchers at the University of Pennsylvania School of Medicine. A protein, whose role in pancreatic development has long been recognized, has been discovered to play an additional and previously unknown regulatory role in the development of cells in the immature endocrine system. These cells ultimately give rise to pancreatic islet cells, which include beta cells.

By carefully defining the developmental steps and genetic circuits that lead to mature beta cells, researchers may be able to one day mimic these developmental processes, thereby facilitating beta-cell growth in the lab, and eventually, new therapies. The findings appear in the July 2009 issue of the Journal of Clinical Investigation.

Wednesday, July 08, 2009

Cellular Dynamics International Reprograms Blood Cells into Stem Cells

Source: Cellular Dynamics International, Inc.
Date: July 8, 2009

Summary:

Researchers at Cellular Dynamics International (CDI) report the ability to generate pluripotent stem cells, which have the ability to generate all tissue types in the body, from very small volumes of ordinary human blood samples. This significant breakthrough provides a readily obtainable source of pluripotent stem cells from the millions of samples in storage at blood repositories and healthcare institutions worldwide. These findings, announced today, will be presented during a poster session beginning at 4:45 p.m. on July 10 at the ISSCR annual meeting in Barcelona, Spain.

Stem cells’ “suspended” state preserved by key step, scientists report

Source: University of California - San Francisco
Date: July 8, 2009

Summary:

Scientists have identified a gene that is essential for embryonic stem cells to maintain their all-purpose, pluripotent state. Exploiting the finding may lead to a greater understanding of how cells acquire their specialized states and provide a strategy to efficiently reprogram mature cells back into the pluripotent state, an elusive step in stem cell research but one crucial to a range of potential clinical treatments. The research was led by University of California, San Francisco scientists. It is being reported Wednesday, July 8, 2009, in the advanced online edition of the journal Nature, and will be published in the journal’s print edition at the end of July.

Monday, July 06, 2009

New discovery points to a new treatment avenue for acute myeloid leukemia

Source: University Health Network
Date: July 6, 2009

Summary:

Dr. John Dick, Senior Scientist at the Ontario Cancer Institute, the research arm of Princess Margaret Hospital, part of the University Health Network, co-led a multinational team that has developed the first leukemia therapy that targets a protein, CD123, on the surface of cancer stem cells that drive acute myeloid leukemia (AML), which is an aggressive disease with a poor outcome. Dr. Richard Lock is leading the clinical trial in Australia that expands on research suggesting that antibodies targeting cancer stem cells significantly reduced the growth of human AML cells that had been transplanted into immune-deficient mice, a laboratory model that mimics the human disease, establishing the therapeutic potential of this type of therapy. The research paper Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells was published in Cell Stem Cell July 2, 2009.

Functional Dendritic Cells Can Be Derived From Embryonic Stem Cells

Source: Geron Corporation
Date: July 6, 2009

Summary:

Geron Corporation today announced the publication of data demonstrating that dendritic cells (DCs) scalably manufactured from human embryonic stem cells (hESCs) exhibit the normal functions of naturally occurring human DCs found in the bloodstream. These findings support the use of hESC-derived DCs in therapeutic vaccine applications for cancer and other diseases. Substituting standardized, off-the-shelf hESC-derived DCs for current approaches using DCs obtained from individual patients may result in more cost effective and reliable approaches to cancer immunotherapy.

The study, authored by Geron scientists and collaborators Prof. Waldmann and Dr. Fairchild at the Sir William Dunn School of Pathology, University of Oxford, appears online in advance of print in the journal Regenerative Medicine.

Thursday, July 02, 2009

Scientists find molecular differences between embryonic stem cells and reprogrammed skin cells

Source: University of California - Los Angeles
Date: July 2, 2009

Summary:

UCLA researchers have found that embryonic stem cells and skin cells reprogrammed into embryonic-like cells have inherent molecular differences, demonstrating for the first time that the two cell types are clearly distinguishable from one another. The data from the study suggest that embryonic stem cells and the reprogrammed cells, known as induced pluripotent stem (iPS) cells, have overlapping but still distinct gene expression signatures. The differing signatures were evident regardless of where the cell lines were generated, the methods by which they were derived or the species from which they were isolated, said Bill Lowry, a researcher with the Broad Stem Cell Research Center and a study author. The study appears in the July 2, 2009 issue of the journal Cell Stem Cell.

Wednesday, July 01, 2009

Human cardiac master stem cells identified

Source Harvard University
Date: July 1, 2009

Summary:

Harvard Stem Cell Institute researchers at Massachusetts General Hospital have identified the earliest master human heart stem cell from human embryonic stem cells - ISL1+ progenitors - that give rise to a family of cells that form the essential portions of the human heart. The discovery, by a group led by Kenneth Chien, director of both HSCI’s Cardiovascular Disease Program and the MGH Cardiovascular Research Center, is particularly important because the cells were found in regions of the heart known as hot spots for congenital heart disease. These latest findings, published today in the journal Nature, build upon and expand earlier work by Chien’s team and others in mice.

Blood stem cell growth factor reverses memory decline in mice

Source: University of South Florida Health
Date: July 1, 2009

Summary:

A human growth factor that stimulates blood stem cells to proliferate in the bone marrow reverses memory impairment in mice genetically altered to develop Alzheimer's disease, researchers at the University of South Florida and James A. Haley Hospital found. The granulocyte-colony stimulating factor (GCSF) significantly reduced levels of the brain-clogging protein beta amyloid deposited in excess in the brains of the Alzheimer's mice, increased the production of new neurons and promoted nerve cell connections. The findings are reported online in Neuroscience and are scheduled to appear in the journal's print edition in August.

Stanford discovery pinpoints new connection between cancer cells, stem cells

Source: Stanford University Medical Center
Date: July 1, 2009

Summary:

STANFORD, Calif. — A molecule called telomerase, best known for enabling unlimited cell division of stem cells and cancer cells, has a surprising additional role in the expression of genes in an important stem cell regulatory pathway, say researchers at the Stanford University School of Medicine. The unexpected finding may lead to new anticancer therapies and a greater understanding of how adult and embryonic stem cells divide and specialize.

"Telomerase is the factor that accounts for the unlimited division of cancer cells," said Steven Artandi, MD, PhD, associate professor of hematology, "and we're very excited about what this connection might mean in human disease." Artandi is the senior author of the research, which will be published in the July 2 issue of the journal Nature. He is also a member of Stanford's Cancer Center.